We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Proximagen Grp | PRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 365.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 365.25 |
| Top Posts |
|---|
Posted at 01/4/2016 21:49 by elgordo For my own reference more than anything else -Most Recent Events 15 Feb 2016 Phase-II development in Osteoarthritis is ongoing in United Kingdom (PO) 01 Dec 2015 PRX 167700 licensed to Roche worldwide 19 Jul 2013 Phase-II clinical trials in Osteoarthritis in United Kingdom (PO) |
Posted at 22/7/2015 14:35 by elgordo In case anyone out there is interested...I have just got hold of the CVR Representative’ In summary, the potential value from the CVRs was derived from two programmes, and their status is as follows: PRX00993 – dead and buried (“discontinued PRX-167700 – Active partnering discussions on back of progress and headline results of Phase IIa osteoarthritis study and planning for IBD clinical studies. “In January 2015 a potential partner proposed terms for supporting Phase II clinical study with an option for commercial rights. Discussions are continuing with this potential partner as well as other potential partners.” So, still some hope of value to be derived from the CVRs, though I believe they expire at the end of August 2017 so time is starting to run quite short. |
Posted at 22/12/2010 12:27 by mike111d Yes well done to the BOD, another good year for PRX. |
Posted at 05/1/2010 10:44 by elgordo Looks like I was wrong about this board "livening up" once PRX announced an acquisition. Admittedly a small deal (and, as far as I can figure, not at a significant premium to MDM's cash balances - £4.3m v £3.5m), but nice to see some activity here. |
Posted at 04/11/2009 20:30 by elgordo Wow, it really is quiet here, isn't it? Clearly the CBT acquisition was too minor to attract any interest. I guess things will liven up when PRX announces its first major acquisition using some of its £50m war chest. |
Posted at 14/7/2008 07:32 by charmer1_23 RNS Number : 9598YProximagen Neuroscience Plc 14 July 2008 For immediate release 14 July 2008 PROXIMAGEN NEUROSCIENCE PLC ('Proximagen' or 'the Company') PROXIMAGEN SIGNS $232 MILLION LICENSING AGREEMENT WITH UPSHER-SMITH TO DEVELOP PRX1 PROGRAMME $6 MILLION EQUITY INVESTMENT IN PROXIMAGEN AT c.200 PENCE PER SHARE BY UPSHER-SMITH ~ Upfront payment, milestone payments totalling up to $232 million payable to Proximagen ~ ~ Royalties payable to Proximagen on worldwide sales ~ London, UK - Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is today pleased to announce it has entered into a worldwide licensing agreement ('the Agreement') with Upsher-Smith Laboratories Inc. ('Upsher-Smith'), the Minnesota-based company which develops, manufactures and markets pharmaceuticals in a number of therapeutic areas. The Agreement covers the development and commercialisation of Proximagen's proprietary PRX1 programme for the symptomatic treatment of Parkinson's disease (PD). Proximagen will receive an upfront payment and milestone payments totalling up to $232 million (£117 million*), plus royalties on global product sales. Highlights of the Agreement: Upsher-Smith will pay Proximagen an upfront payment and milestone payments totalling up to $232 million (£117 million*) upon the PRX1 programme reaching certain development and sales milestones; According to the terms of the Agreement, Upsher-Smith expects to make a $6 million (£3.03 million*) equity investment in Proximagen at c.200 pence per share, a premium of c.100% to the closing share price of Proximagen on Friday 11 July 2008; Upon this first equity investment, Upsher-Smith will hold 7.1% of the enlarged issued share capital of Proximagen; Under the terms of the Agreement, Proximagen is entitled to up to double-digit royalties on global product sales on an escalating royalty basis; and Upsher-Smith will be responsible for the worldwide development and commercialisation of PRX1 under the direction of a joint steering committee on which there will be representation from Proximagen. Upsher-Smith Upsher-Smith is an established and rapidly growing, privately-held company based in Minneapolis, Minnesota. It is a fully integrated pharmaceutical company with expertise in product development, formulations research, clinical research, pharmacovigilance, manufacturing, marketing and sales, as well as legal, regulatory affairs and quality assurance. Upsher-Smith's core focus has traditionally been on developing branded and generic products in the therapeutic areas of women's health, dermatology, cardiology and neurology, and the Agreement demonstrates Upsher-Smith's strategic intent to broaden its pipeline in disorders of the central nervous system. PRX1 - Meeting a high unmet market need Proximagen's PRX1 programme, which is currently in the pre-clinical stage of development, has been designed to provide a 'super' version of L-DOPA, the current gold-standard treatment for PD, to overcome the problems associated with the current treatment of PD. The results from the PRX1 development programme are deemed by scientific experts to be highly significant and the drug candidate has the potential to become the drug of first choice for addressing motor symptoms associated with PD. The worldwide market for PD therapeutics is estimated to be valued at more than $2.5 billion per annum (source: IMS Health). The PRX1 drug candidate has shown significantly increased biological half-life (the period of time required for the concentration or amount of drug in the body to be reduced by one-half) in pre-clinical studies compared with L-DOPA. This could represent a significant advancement in the current treatment of patients, since the existing L-DOPA controlled release preparations increase the half-life of L-DOPA by less than two hours. By increasing the plasma half-life in patients, the desired effect of Proximagen's drug candidate, compared to the traditional L-DOPA, would be to reduce the peak and trough blood levels associated with involuntary movements in PD, reduce the number of daily doses needed and thereby improve patients' sleep and general quality of life. Furthermore, in pre-clinical studies, the administration of the PRX1 drug candidate at dose equivalents to L-DOPA produced maximal reversal of motor disability with virtually no dyskinesia side effects. Commenting on the Agreement, Kenneth Mulvany, CEO of Proximagen Neuroscience plc, said: 'We are delighted to have partnered our PRX1 programme with Upsher-Smith, a company whose ambitions for meeting the needs of Parkinson's disease patients match our own and whose excellence in clinical development and commercialistion complements Proximagen's expertise in research and development. We are confident that the two companies will make excellent partners, and together, we look forward to maximising the potential of this exciting programme. 'This deal demonstrates Proximagen's ability to leverage our expertise in Parkinson's disease to discover first class drug candidates, as well as our ability to commercialise early stage products. 'Proximagen already has a strong cash balance and is now very well positioned to continue investment in its pipeline and exploit commercial opportunities as they arise to continue building value for shareholders.' Tom Burke, Executive Vice President Commercial Operations for Upsher-Smith, added: 'PRX1 is a novel pharmaceutical drug candidate that we believe could become a leader in the treatment of Parkinson's disease. We are excited by the potential market opportunity and the profile of the PRX1 programme drug candidate. We are also delighted to be working with Proximagen, a company with world class expertise in the field of Parkinson's disease. 'Upsher-Smith's strength in the development and commercialisation of pharmaceutical products will enable us to successfully take the PRX1 programme to the next stage of development and beyond. There is a clear unmet medical need for the treatment of Parkinson's disease and we look forward to the successful development of PRX1.' * Exchange rate used: £1=$1.98 For further information, please contact: Proximagen Neuroscience plc Tel: 020 7848 6938 Kenneth Mulvany, Chief Executive James Hunter, Finance Director Buchanan Communications Tel: 020 7466 5000 Mary-Jane Johnson, Tim Anderson, Catherine Breen Canaccord Adams Limited (NOMAD) Tel: 020 7050 6500 Mark Williams, Adria Da Breo-Richards About Proximagen Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease. Proximagen is building a development pipeline to address the significant medical needs of these patients and has made substantial progress in five proprietary programmes. Proximagen anticipates out-licensing its programmes at early stages up to and including Phase II proof of concept studies and commercialising carefully selected in-licensed and collaborative programmes. Proximagen joined the AIM market of the London Stock Exchange in March 2005. For more information please visit the Company's web site: www.proximagen.com. About Upsher-Smith Upsher-Smith is pursuing improved drug therapies to improve people's lives. The evolution of our company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Our perspective is not 'more products,' but the right products that make people's lives better. At every level of our business, we are driven to be the best. Upsher-Smith Laboratories is focused on market expansion in women's health, dermatology, and cardiology, in addition to developing products for neurology. Our most valuable resources are the people who create and innovate products to support healthcare professionals. For more information, please visit Upsher-Smith's website at www.upsher-smith.com This information is provided by RNS The company news service from the London Stock Exchange END AGREAEXDFSEPEAE |
Posted at 02/1/2008 08:16 by mtness First post in 3 weeks on this thread - PRX up sharply this morning - could be because it was tipped for 2008 by the Independent - |
Posted at 08/12/2007 19:52 by mike111d If so, he could well be proven correct and FWIW I also have a high regard for KM and the PRX business model. |
Posted at 01/9/2007 22:58 by mike111d Martin, with regards to the offer I would not expect to hear anything prior to sometime in October in all likelihood, as being acquired is not necessarily what the company or the major holders desire. So they continue to work through the required process and if a sufficiently compelling offer materialises then we will obviously get to hear of it but his is not why I bought into PRX or why I continue to hold.FYI, the major holder information on the web site whilst has been updated to reflect the holdings above the 3% threshold, you should be aware that Gartmore still hold a little over 5% but this is not being reported as the holding was recently split across a number of nominee accounts all of which are below the 3% level. Overall I can account for named founder shareholders, institutions and directors holding 87.9% of the company. Near term there is a bit of an overhang to clear resulting from the recent sale of 270k shares by USS. It would appear that the other institutional holders have no intention of reducing their positions. In fact one of the things that I was very encouraged by when researching PRX was the fact that since admission the shares controlled by major shareholders has increased steadily from 51.44% to 87.9% today. In terms of clinical updates, the next announcement I anticipate is confirmation of phase I trials starting early in 2008 for PRX1. Secondary to this is the progression of the PRX5 programme. |
Posted at 29/8/2007 12:26 by mike111d Martin, it looks that way. I can tell you that the deal with Elan for PRX4 is fairly benign, with Elan funding developments and having first call with a trigger clause in the event of PRX being acquired. On that subject, this remains under review but the key here is that the offers are / were totally unsolicited and the company and key stake holders will not be proposing that an offer be accepted unless it were north of the 145p admission price. Happy for this remaining under the radar for now, as I would like to add further pending developments elsewhere. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
